Home›Trial›NCT06215716
🔬NCT06215716Phase 3RECRUITING

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Study Summary

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.

Conditions
NASH With FibrosisMASH With Fibrosis
Interventions / Drugs
EfruxiferminPlacebo
View on ClinicalTrials.gov ↗
Sponsor
AKRO
Akero Therapeutics
Metabolic Disease
B66/100
Study Details
Enrollment1650 participants
Primary Completion—
Lead SponsorAkero Therapeutics, Inc
Data Retrieved2026-04-11 02:53:02.345385+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.